Treatment of Relapsed or Refractory Neuroblastoma With Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary) ; Natural killer cell therapy (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 31 May 2018 Status changed to recruiting.
- 09 Feb 2018 Planned initiation date changed from 1 Nov 2017 to 1 Apr 2018.
- 18 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.